Markets
markets
Luke Kawa

Stocks slump after Powell warns that we’re “early days” of tariff-driven inflation

The Federal Reserve kept rates unchanged at a range of 4.25% to 4.5%, as was nearly universally expected by economists.

In the statement, monetary policymakers noted that US economic growth “moderated in the first half of the year.” Previously, they had described the expansion as “solid.”

Stocks and bonds were little changed in the immediate aftermath of the decision, but not for long. The SPDR S&P 500 ETF slumped to session lows, falling 0.5% after being up as much as 0.4%, as Fed Chair Jay Powell warned that more tariff-fueled inflation would be in the offing and said it was his view that the economy calls for “moderately restrictive” monetary policy for now.

That caused traders to no longer price in a full 25-basis point interest rate cut by October, and two-year Treasury yields jumped from a low of 3.86% to as high as 3.94%. The Dollar Spot Index extended its daily gain to 0.9%.

“Powell wanted the market to be data dependent coming into an important few months of data. 50/50 odds of cutting or holding in each meeting for the rest of the year is a nice benchmark for that given where we are now and what the June baseline was,” said Peter Williams, an economist at 22V Research. “That is what we’re ending up with after his honest descriptions of the risks around the baseline, the inflationary pressures, and labor market data.”

In this decision, the central bank broke a 259-meeting streak in which fewer than two Fed governors dissented.

Governors Michelle Bowman and Christopher Waller preferred a 25-basis point cut at this meeting.

Both have publicly disagreed with the thrust of the committee before. In September, Bowman had delivered a hawkish dissent, believing the central bank should have lowered rates by only 25 basis points rather than 50 basis points. Waller, for his part, disagreed with the central bank’s decision in March to slow the pace its balance sheet would shrink at. Bowman and Waller were both appointed by President Trump during his first term.

Heading into the decision, about 44 basis points of easing were priced in by year-end, per Fed funds futures. That’s loosely aligned with the central bank’s June dot plot, which showed the median official anticipated 50 basis points of easing by the end of 2025 if the economy unfolded in line with expectations.

More Markets

See all Markets
markets

Broadcom soars on Google’s plans for up to $185 billion in capex this year

Google’s capex guidance is Broadcom’s earnings guidance.

The hyperscaler and search giant said its 2026 capex budget would be between $175 billion and $185 billion, 55% higher than Wall Street had anticipated.

Accordingly, shares of the custom chip specialist soared in after-hours trading and have held onto those gains in early action on Thursday, currently up 5.6% as of 4:35 a.m. ET.

Broadcom has enjoyed a halo effect from Google’s capex plans and the success of its Gemini 3 model (trained on TPUs the two companies codesigned) over the past year.

But the custom chip designer had tumbled after its most recent earnings report, with some analysts attributing the decline to the dearth of new customer announcements. But who needs new customers when your current ones are opening their wallets this much?!?

Accordingly, shares of the custom chip specialist soared in after-hours trading and have held onto those gains in early action on Thursday, currently up 5.6% as of 4:35 a.m. ET.

Broadcom has enjoyed a halo effect from Google’s capex plans and the success of its Gemini 3 model (trained on TPUs the two companies codesigned) over the past year.

But the custom chip designer had tumbled after its most recent earnings report, with some analysts attributing the decline to the dearth of new customer announcements. But who needs new customers when your current ones are opening their wallets this much?!?

(J. Edward Moreno/Sherwood News)

Novo and Lilly agree prices are falling — and disagree on what comes next

Novo Nordisk and Eli Lilly are cutting prices to reach more patients — with sharply different expectations about what that means for sales.

markets

Ozempic is no longer the most searched for GLP-1 in the US

Ozempic, the popular diabetes drug made by Novo Nordisk, used to be shorthand for an entire class of diabetes and weight-loss medications. Not anymore.

According to Google Trends data, as of January, more people in the US are searching for Eli Lilly’s weight-loss shot, Zepbound, than Ozempic. At the same time, interest in the word “Ozempic” now sits roughly on par with searches for “peptides,” a catchall term for a booming, loosely regulated category of experimental supplements.

The numbers hint at a cultural shift: Ozempic is no longer the only word people reach for when they think about weight-loss drugs. The market — and the vocabulary around it — is fragmenting.

This shift also reflected in sales numbers. For several quarters now, Lillys diabetes and weight-loss drugs have outsold Novos, and that gap is expected to widen this year.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.